Policy / Pricing A ‘hijacked plane’: CDC, under RFK Jr.’s influence, trades science for dogma BioPharma DiveA series of controversial policy changes directed by the HHS secretary have left experts fearful of the future implications for public health.Policy / PricingRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) BioPharma Dive A series of controversial policy changes directed by the HHS secretary have left experts fearful of the future implications for public health. Policy / PricingRead full story Post navigation Previous: Agios mulls early FDA filing for sickle cell therapyNext: FDA, after turbulent year, leaves drugmakers guessing on its direction Related Stories Policy / Pricing Mid-cap biotechs join Trump’s latest round of drug pricing deals pharminent September 1, 2026 Policy / Pricing MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones pharminent August 27, 2026 Policy / Pricing MFN affecting Swiss medicines access, says Interpharma pharminent August 13, 2026